1,4-Diethyl-2-methylpiperazine | 98952-13-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1,4-Diethyl-2-methylpiperazine
• CAS: 98952-13-7
• 化学式: C₉H₂₀N₂
• 分子量: 156.27
• InChiKey: DNPRCPUUZUVBMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• NOVEL AZABICYCLOHEXANES
  申请人：Jain Rajseh

  公开号：US20120165320A1

  公开（公告）日：2012-06-28

  The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.

  本发明涉及公式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体包括R和S异构体，多晶型，前药，代谢物，盐或溶剂的形式。该发明还涉及用于合成公式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体，多晶型，前药，代谢物，盐或溶剂的过程。
• [EN] B-RAF KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE B-RAF
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011117381A1

  公开（公告）日：2011-09-29

  The present invention encompasses compounds of general formula (1) where in the groups R0to R3 and L are defined as in claim 1, which are suitable for the 5 treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

  本发明涵盖了一般式（1）中的化合物，其中基团R0至R3和L的定义如权利要求书中所述，这些化合物适用于治疗以细胞过度或异常增殖为特征的疾病，包含这种化合物的药物制剂以及它们作为药物的用途。
• Benzimidazole-4-Carboxamide Derivatives, Their Preparation Methods, Pharmaceutical Compositions And Their Uses
  申请人：Luo Xianjin

  公开号：US20110269766A1

  公开（公告）日：2011-11-03

  The present invention relates to the benzimidazole-4-carboxamide derivatives, their preparation methods, pharmaceutical compositions and their uses; wherein X represents monosubstituted or bissubstituted or polysubstitued C 1 -C 14 alkoxy, monosubstituted or bisubstituted or polysubstitued C 1 -C 14 alkyl, monosubstituted or bisubstituted or polysubstitued C 2 -C 14 alkenyl, monosubstituted or bisubstituted or polysubstitued C 6 -C 14 aryl, or monosubstituted or bisubstituted or polysubstitued 5 to 6 membered heterocyclic group, or monosubstituted or bisubstituted or polysubstitued fused ring group containing nitrogen heteroatom; Y represents hydrogen, monosubstituted or bisubstituted or polysubstitued C 1 -C 16 alkyl, monosubstituted or bisubstituted or polysubstitued C 6 -C 12 aryl, or monosubstituted or bisubstituted or polysubstitued 5 to 6 membered heterocyclic group, or monosubstituted or bisubstituted or polysubstitued fused ring group containing nitrogen heteroatom. The derivatives of the present invention have the functions of antiviral medicine.

  本发明涉及苯并咪唑-4-羧酰胺衍生物，其制备方法，药物组合物及其用途；其中X代表单取代或双取代或多取代的C1-C14烷氧基，单取代或双取代或多取代的C1-C14烷基，单取代或双取代或多取代的C2-C14烯基，单取代或双取代或多取代的C6-C14芳基，或单取代或双取代或多取代的含氮杂原子的5至6成员杂环基，或单取代或双取代或多取代的融合环基团；Y代表氢，单取代或双取代或多取代的C1-C16烷基，单取代或双取代或多取代的C6-C12芳基，或单取代或双取代或多取代的5至6成员杂环基，或单取代或双取代或多取代的融合环基团含氮杂原子。本发明的衍生物具有抗病毒药物功能。
• Process for the production of purine nucleoside compounds
  申请人：Torii Takayoshi

  公开号：US20050171126A1

  公开（公告）日：2005-08-04

  2′,3′-didehydro-2′,3′-dideoxypurine nucleoside compounds and 2′,3′-dideoxypurine nucleoside compounds may be produced efficiently by treating a 3′-deoxy-3′-bromopurine nucleoside compound with a perfluoroalkanesulfonyl fluoride in the presence of a base to give a 2′,3′-didehydro-2′,3′-dideoxypurine nucleoside compound, which may be converted to a 2′,3′-dideoxypurine nucleoside compound, by catalytic hydrogenation.

  2′,3′-二去氢-2′,3′-二脱氧嘌呤核苷化合物和2′,3′-二脱氧嘌呤核苷化合物可以通过在碱的存在下用全氟烷磺酰氟处理3′-脱氧-3′-溴嘌呤核苷化合物来高效制备，从而得到2′,3′-二去氢-2′,3′-二脱氧嘌呤核苷化合物，通过催化氢化可以将其转化为2′,3′-二脱氧嘌呤核苷化合物。
• Piperidine Derivatives as Histamine H3 Receptor Ligands
  申请人：Folmer James

  公开号：US20080064706A1

  公开（公告）日：2008-03-13

  Compounds of formula: wherein Ar 1 and Q are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the treatment of depression.

  该化合物的公式为：其中Ar1和Q如规范所定义，以及该化合物的盐、对映体和包括该化合物的药物组合物已经准备好。它们在治疗方面是有用的，特别是在治疗抑郁症方面。

表征谱图